Vilon is a synthetic dipeptide (L-Lys-L-Glu) belonging to the Khavinson family of short peptide bioregulators developed at the St. Petersburg Institute of Bioregulation and Gerontology. It is one of the shortest peptides in that class and was derived from amino-acid analysis of thymus-derived preparations.
It has been investigated primarily in Russian biogerontology and immunology research examining thymic tissue, immune senescence, and gene-expression changes in aging cellular models.
Research proposes that Vilon acts through peptide-chromatin interactions that modulate gene expression in immune and other cell types, with study reports describing deheterochromatinization (loosening of condensed chromatin) that can reactivate genes silenced in aging cells [2].
In immunology models it is described as influencing thymocyte differentiation and T-cell maturation markers.
Immune modulation - studied for effects on thymocyte differentiation and T-cell markers [2].
Chromatin/gene-expression models - investigated for deheterochromatinization in aging cells [2].
Oncogerontology models - examined for effects on spontaneous tumor incidence and lifespan in mice [1].
Thymic involution research - characterized in age-related immune-tissue studies [2].
📋 How published studies were conducted — a research reference summarizing study designs from the literature. This is not usage, dosing, or administration guidance. K4 Elite does not provide dosing instructions; determining any research protocol is the sole responsibility of the qualified researcher.
Anisimov and colleagues reported that the synthetic dipeptide Vilon (L-Lys-L-Glu) administered to mice was associated with reduced incidence of spontaneous tumors and increased mean lifespan relative to controls in their study cohort [1].
Additional Khavinson-group studies describe Vilon in models of thymic tissue and immune-cell maturation, reporting changes in CD-marker expression among thymocytes [2].
Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.
ThymalinSynergistic
Vilon was derived from thymus-preparation analysis; studied within the same immunoregulatory research lineage.
EpithalonCompatible
Both are short Khavinson bioregulator peptides examined in aging-related models; sometimes discussed together in that literature.
Thymogen (Glutamyl-Tryptophan)Compatible
Related short immunoactive peptide from the same research tradition.
Citations below are retrieved automatically from PubMed (NIH / U.S. National Library of Medicine) for the search term “Vilon”, newest first. They are listed as literature references for research purposes only. K4 Elite does not summarise, interpret or endorse their findings.
It is the dipeptide L-Lys-L-Glu (lysylglutamic acid), one of the shortest peptides in the Khavinson bioregulator class [2].
What kind of research exists on it?
Mostly Russian biogerontology and immunology studies in animal and cellular models examining immune tissue, chromatin, and aging endpoints [1][2].
Is this product intended for human use?
No. This entry is for research and informational purposes only and is not dosing guidance or a therapeutic recommendation.
Disclaimer: This profile summarizes published preclinical and laboratory research for reference only. It is not medical advice and makes no claim of safety or efficacy in humans. Determining any research protocol is the sole responsibility of the qualified researcher. Products are sold strictly for in-vitro research and have not been evaluated by the FDA.
K4 Elite